What Management Said

Read the full Q3 2025 transcript ↗

Jake will then review our financial results for the fiscal third quarter of 2025, as well as discuss the updated financial guidance for the fiscal year 2025. This milestone means that 100% of our revenue is now flowing through Embecta's own systems and marks the successful conclusion of a multi-year complex separation program. and Canada has significantly advanced, with greater than 90% of our North American revenue base having been changed over to Embecta-branded products. Several of these companies have already signed agreements with us and placed purchase orders for our pen needles.

Together, the co-packaging and retail packaging prospects represent a significant long-term opportunity that could generate more than $100 million in annual revenue for Embecta by 2033. With stand-up-related cash usage largely behind us and cost optimization initiatives underway, we believe we are well positioned to continue strengthening our balance sheet, thereby enabling us to make future organic and inorganic investments. Turning to some fiscal third quarter highlights, third quarter revenue reached all-time highs, totaling $295.5 million. During the third quarter of fiscal year 2025, Embecta generated $295.5 million in revenue, reflecting growth of 8.4% on an as-reported basis or 8% on an adjusted constant currency basis.

Within the U.S., revenue for the quarter totaled $160.2 million, representing year-over-year growth of 11.6% on an adjusted constant currency basis. This performance was aided in part by a favorable comparison to the prior year period, as well as the aforementioned rebate reserve adjustments and timing of orders. We expect the timing-related benefits from these orders to reverse in the fourth quarter. Turning to our international business, revenue for the third quarter totaled $135.3 million, representing growth of 5.0% on a reported basis and 4.2% on an adjusted constant currency basis.

What went well
  • Third quarter revenue reached an all-time high of $295.5 million, up 8.4% as-reported and 8% adjusted constant currency, significantly exceeding expectations (about $14 million above internal estimates).
  • U.S. revenue of $160.2 million grew 11.6% adjusted constant currency, aided by favorable rebate reserve adjustments and order timing.
  • Adjusted EPS of $1.12, up from $0.74 in the prior year period; adjusted net income of $65.5 million, up from $43 million.
  • Adjusted operating income and margin of $109.1 million and 36.9%, up from $83.3 million and 30.6% prior year.
  • Adjusted EBITDA and margin of approximately $131 million and 44.3%, up from $99.2 million and 36.4% prior year.
  • Completed the ERP, shared services, and distribution implementation in India, the last market on BD systems, marking 100% of revenue flowing through Embecta's own systems and concluding the multi-year separation program.
  • Paid down $52.4 million of Term Loan B in Q3, bringing year-to-date debt reduction to $112 million and exceeding the fiscal 2025 target of approximately $110 million with a quarter to spare.
  • Generated approximately $81 million in free cash flow (about $55 million normalized for ~$26 million of receivables factoring); cash balance approximately $234 million; net leverage 3.2x.
  • Restructuring plan substantially complete, expected to drive $7 million-$8 million of pre-tax savings in the second half of fiscal 2025 (approximately $15 million annualized).
  • Product family growth in Q3: pen needles +6.8%, syringes +14.5%, safety products +6.5%, contract manufacturing +47.2%.
What went wrong
  • International revenue growth of 5.0% reported and 4.2% adjusted constant currency was partially offset by a year-over-year decline in China.
  • China revenue expected to be slightly lower sequentially in Q4 due to geopolitical/trade dynamics, a preference for local Chinese brands, and distributor inventory rebalancing.
  • Q3 adjusted gross margin declined to 67.2% from 69.8% prior year, driven by a smaller favorable profit and inventory adjustment than the large one in Q3 2024.
  • Q3 timing benefits (distributor orders ahead of July 4 and ~$7 million rebate reserve adjustment) are expected to reverse and not recur in Q4.
  • Adjusted tax rate increased to approximately 25% in Q3 2025 from approximately 22% in Q3 2024.
  • Implied Q4 revenue midpoint of about $265 million represents a sequential step down from Q3's $295 million, with roughly half driven by the absence of distributor orders, plus the rebate reserve non-recurrence and a ~$3 million FX headwind.
  • Q4 operating margin expected to step down to around 24% at the midpoint, with revenue impact driving ~400 bps and profit and inventory (a Q3 benefit, slight Q4 expense) driving ~300 bps of the sequential decline.

Guidance Changes

MetricPeriodCurrent guidance
———
———
———
———
———
———
———
———
———
———

Performance Breakdown

MetricYoYNote
— — —
— — —
— — —
— — —
— — —
— — —
— — —
— — —
— — —

Earnings Call Themes & Trends

TopicPrevious mentionCurrent periodTrend
————
————
————
————
————
————
————
————

Q&A Summary

More on Embecta Corp.

Company

Embecta Corp. overview
Facet

Financials
Transcript

Q3 2025 call
Reported 2025-08-08 · figures from the Embecta Corp. Q3 2025 earnings call.

See how VectorShift works for your firm

Request Demo